Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017 (2017), Article ID 7680576, 9 pages
https://doi.org/10.1155/2017/7680576
Review Article

Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease

1Department of Endocrinology, Metabolism, and Genetics, Jiangxi Provincial Children’s Hospital, Nanchang, Jiangxi, China
2Pediatric Research Institute, Department of Pediatrics, University of Louisville, Louisville, KY, USA
3Department of Cardiovascular Disorders, The First Hospital of Jilin University, Changchun, China
4Department of Cardiovascular Disorders, Jiangxi Provincial Children’s Hospital, Nanchang, Jiangxi, China

Correspondence should be addressed to Yu Yang; moc.liamg@yexjhhyy

Received 2 May 2017; Accepted 13 July 2017; Published 8 August 2017

Academic Editor: Robertina Giacconi

Copyright © 2017 Yu Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Diabetic kidney disease (DKD) is a widespread chronic microvascular complication of diabetes mellitus (DM), affects almost 30–50% of patients, and represents a leading cause of death of DM. Serotonin or 5-hydroxytryptamine (5-HT) is a multifunctional bioamine that has crucial roles in many physiological pathways. Recently, emerging evidence from experimental and clinical studies has demonstrated that 5-HT is involved in the pathogenesis of diabetic vascular complications. The 5-HT receptor (5-HTR) antagonists exert renoprotective effects by suppressing oxidative stress, suggesting that 5-HTR can be used as a potential target for treating DKD. In this review, therefore, we summarize the published information available for the involvement of 5-HT and 5-HTR antagonists in the pathogenesis of various diabetic complications with a particular focus of DKD. We conclude that 5-HTR is a potential therapeutic target for treating DKD, as it has been successfully applied in animal models and has currently being investigated in randomized and controlled clinical trials.